The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
May 16th 2024
Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.
Stearns Elaborates on the Evolution of ADCs in HER2+ and HER2-Low Breast Cancer
Vered Stearns, MD, FASCO, discusses how DESTINY-Breast04 has shifted the treatment paradigm for patients with HER2-low breast cancer, the exploration of treatment combinations being optimized in breast cancer, and the expansion of the treatment paradigm in triple-negative breast cancer.
Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer
Adding atezolizumab to neoadjuvant standard of care therapy for HER2-positive early breast cancer did not result in a better pathologic complete response compared with placebo, according to findings from the phase 3 IMpassion050 trial.
Stanford Faculty Break Down Advancements in Women’s Cancer Care
Advancements in treatment options across the spectrum on women’s cancers include de-escalating therapy in HER2-positive breast cancer, using tisotumab vedotin-tftv in cervical cancer, shifting therapies to the frontline setting in endometrial cancer, and using checkpoint inhibitors in ovarian cancer.
HER2 Expression Is a Key Determinant of Trastuzumab Deruxtecan Activity
HER2 expression appeared to be a significant predictor for response to fam-trastuzumab deruxtecan-nxki, according to findings from a biomarker analysis of patients with metastatic breast cancer in the phase 2 DAISY trial.
Trastuzumab Deruxtecan Maintains QOL and Global Health Status in HER2+ Metastatic Breast Cancer
Overall health status and quality of life were maintained among patients with HER2-positive metastatic breast cancer who were treated with fam-trastuzumab deruxtecan-nxki compared with those who received ado-trastuzumab emtansine.
Neoadjuvant and Adjuvant Therapy Elicit Similar Efficacy in Early-Stage HER2+ Breast Cancer
Neoadjuvant therapy generated similar benefits to adjuvant therapy in patients with early-stage, HER2-positive breast cancer treated in China, suggesting that neoadjuvant therapy should be used in this patient population.
FDA Grants Regular Approval to Trastuzumab Deruxtecan for Select HER2+ Metastatic Breast Cancer
The FDA has approved fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti–HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within 6 months of therapy completion.
Tucatinib Plus T-DM1 Represents Another Potential Therapy in High-Risk HER2-Positive Breast Cancer
Heather McArthur, MD, MPH, discusses key treatment developments in early-stage and metastatic HER2-positive breast cancer and triple-negative breast cancer, plus ongoing research at UT Southwestern Harold C. Simmons Comprehensive Cancer Center.
Recent FDA Approvals Signal Revolution in HER2+ Breast Cancer Treatment
April 11th 2022Mridula George, MD, discusses the variety of innovative HER2-positive breast cancer treatment options that have recently been approved or are undergoing investigation in clinical trials to broaden the standards of care for patients in this subgroup.
Hurvitz Highlights Practice-Changing DESTINY-Breast03 Data in HER2+ Metastatic Breast Cancer
Sara A. Hurvitz, MD, medical oncologist and medical director at the Jonsson Comprehensive Cancer Center Clinical Research Unit, discussed pivotal findings in the HER2-positive treatment landscape that possess the potential to change practice.
Risk-Adaptive Approaches Offer Safer, Effective Strategies for Early-Stage HER2+ Breast Cancer
March 5th 2022The integration of HER2-targeted therapies into the treatment paradigm for patients with early-stage breast cancer, specifically the standard trastuzumab, has shifted focus away from whether patients should receive to how and when they should receive treatment with these agents.
Brain Metastases Are Now More Treatable in HER2+ Metastatic Breast Cancer
The treatment of patients with HER2-positive metastatic breast cancer can now be tailored based on the presence of active central nervous system disease, due to substantial advances made in the past few years into small molecule inhibitors and macromolecule biologics.
Addressing Cardiotoxicity in Breast Cancer Requires Multifaceted Approach
Clinicians with patients who are experiencing cardiotoxicity as a result of their breast cancer treatment should address the cardiotoxicity using a team-oriented approach based on guideline-directed therapies.
Patients with HER2-positive, early-stage breast cancer who achieved a pathologic complete response after receiving HER2-targeted therapy experienced better outcomes in terms of disease-free survival and overall survival vs those who did not, according to data from a real-world study.
FLAMINGO-01 Trial Examining Adjuvant GLSI-100 in HER2+ Breast Cancer Approaches Initiation
Significant progress has been made toward the initiation of the phase 3 FLAMINGO-01 trial, which will evaluate the combination of the immunotherapy GP2 with granulocyte macrophage colony stimulating factor in the adjuvant treatment of HER2/neu- and HLA-A*02–positive patients following surgery and trastuzumab-based therapy.